If you or someone you love has ever spent a night wrestling with a CPAP machine, or woken up feeling more exhausted than when ...

The drug, Mazdutide, is the world's first and currently only GCG/GLP-1 dual receptor agonist targeting both weight loss and ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...

As congressional Republicans attempt to cut Medicaid spending, Democratic Gov. Katie Hobbs signed a bill that could expand ...

For patients with a body mass index (BMI) of 70 or higher, metabolic surgery is a highly effective treatment for this form of ...

A new study looked at the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. At the end of the 72 ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

About 8 million American teens, or 23% of people ages 12 to 19, have obesity, up from 5% in 1980, according to U.S.

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.